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Session: Disease & Treatment 89chondrocytes. Rebamipide down-regulated the mRNA expression of IL-1b, TNF, and
NF-kB, thus Rebamipide had an anti-inflammatory effect in chondrocytes. Rebami-
pide down-regulated catabolic factors (MMP3, MMP13, and ADAMTS5) in chondro-
cytes. Injection of Rebamipide could prevent articular cartilage degeneration for
six weeks. These findings indicate that intra-articular injection of Rebamipide pre-
vents matrix breakdown and the development of OA. In conclusion, intra-articular
injection of Rebamipide prevented articular cartilage degeneration for six weeks
in murine models of osteoarthritis, Rebamipide down-regulated catabolic factors,
and up-regulated anabolic factors in human chondrocytes. Rebamipide could be
an important candidate for prevention of articular cartilage degeneration.
http://dx.doi.org/10.1016/j.jot.2016.06.06464
STRUCTURAL SIMULATION OF ADENOSINE PHOSPHATE VIA PLUMBAGIN AND
ZOLEDRONIC ACID COMPETITIVELY TARGETS JNK/Erk TO SYNERGISTICALLY
ATTENUATE OSTEOCLASTOGENESIS IN A BREAST CANCER MODEL
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Objective: The treatment of breast cancer and subsequent osteolysis remains a
challenge in clinical settings. The aim of this study was to explore the effect
and mechanism of combined treatment with zoledronic acid (ZA) and plumbagin
(PL), a widely investigated component derived from Plumbago Zeylanica, against
breast cancer and cancer-induced osteoclastogenesis.
Methods: Quantitative synergism was evaluated using Compusyn software with
determined combination index (CI) and drug reduction index (DRI) values. The
attenuated malignancies after dual-drug treatment against breast cancer cells
were evaluated with a CCK-8 assay, flow cytometry, and a transwell assay. The
cancer-associated osteoclast formation in vitro after stimulation of receptor acti-
vator for nuclear factor-kB ligand (RANKL) or conditioned medium from MDA-MB-
231 human breast cancer cells upon murine bone marrow-derived monocytes
(BMMs) and human peripheral blood mononucleated cells (hPBMCs), respectively,
were assessed with tartrate-resistant acid phosphatase (TRAcP) staining. Western
blot, real-time PCR, homogeneous time-resolved fluorescence (HTRF) assay, and
molecular docking were used to unravel the underlying synergistic anti-tumorigen-
esis and anti-osteoclastogenesis mechanisms. Non-invasive imaging system (IVIS),
mCT scanning, and immunohistochemistrical analysis were deployed to investigate
the anti-tumorigenesis and anti-osteoclastogenesis effects in vivo after dual-drug
treatment in an intra-tibiae breast cancer model.
Results: We found that the combination of PL and ZA triggered cytotoxicity
(CIZ0.26), induced apoptosis, and inhibited migration of breast cancer cells syner-
gistically. When the breast cancer cells were transfected with specific siRNA against
Notch-1, the combination of ZA and PL markedly increased the expression of Bcl-2.
Combined treatment also suppressed cell viability of precursor osteoclasts and syn-
ergistically inhibited MDA-MB-231 induced osteoclast formation (CIZ0.28) with the
abrogation of RANKL-induced activation of NF-kB/MAPK pathways. Molecular dock-
ing suggested a putative binding area within JNK/Erk protease active sites through
structural mimicking of adenosine phosphate (ANP) by the spatial combination of
PL with ZA. A HTRF assay further illustrated the direct competitiveness of the
dual drugs against ANP docking to phosphorylated JNK/Erk, contributing to the
inhibited downstream expression of c-Jun/c-Fos/NFATc-1. Then, in vivo testing
demonstrated that the combined administration of PL and ZA attenuated breast
cancer growth in the bone microenvironment. Additionally, these molecules pre-
vented the destruction of the proximal tibia, with significant reduction of TRAcP
positive osteoclast cells and potentiation of apoptotic cancer cells, to a greater
extent when combined than when the drugs were applied independently.
Conclusion: The combination treatment with PL and ZA could significantly and
synergistically inhibit tumorigenesis and suppress osteoclastogenesis both in vitro
and in vivo by modulating Notch-1-Bcl-2 signalling and simulating the spatial struc-
ture of adenosine phosphate to competitively inhibit phosphorylation of JNK/Erk.
http://dx.doi.org/10.1016/j.jot.2016.06.06567
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Introduction: Tenascin-C (TNC) is an extracellular matrix glycoprotein. While the
expression is repressed in normal adult tissues, it reappears under pathological
conditions such as wound healing, regeneration, and tumorigenesis. In articular
cartilage, TNC expression is associated with development and is almost absent inadult cartilage. In diseased joints, including those with osteoarthritis (OA), TNC
was highly recurring in cartilage. Our previous studies have demonstrated that
full-length TNC promoted chondrocyte proliferation and increased proteoglycan
content in vitro, and promoted the repair of full-thickness osteochondral defects
in rabbits. In this study, we examined the effects of full-length TNC on joint carti-
lage repair and on synovial inflammation in full-thickness osteochondral defects
model mice. In addition, we performed an in vitro study to reveal the mechanism
of repairing cartilage using full-length TNC.
Methods: Full-length TNC was purified from culture supernatant of human glioma
cells U-251 MG. Male 8-week-old BALB/c strain mice were used. In vivo study: Full-
thickness osteochondral defects were created in the centre of the femoral
trochlea with a hand micro-drill equipped with a 0.3-mm diameter drill-bit. The
defect was filled with TNC (group A: 100mg/ml, group B: 10mg/ml, group C: empty)
by direct administration. Mice were sacrificed at 1, 2, 3, and 6 weeks postopera-
tively (nZ10 knees in each groups at every time point), and whole knee joints
were removed by dissection. Histological examinations were made using haema-
toxylin & eosin (H-E) and Safranin-O (Saf-O) staining. Cartilage repair was evalu-
ated using the modified WAKITANI score. Synovitis was evaluated using synovitis
score according to Krenn. In vitro study: Human cartilage specimens were obtained
from patients who underwent total knee arthroplasty for the treatment of OA.
Chondrocytes were isolated and cultured and they were treated with 0mg/ml,
1mg/ml, or 10mg/ml of TNC. We compared the expression of numerous kinds of
mRNA for every dose by real-time PCR. We evaluated the expression of TNC, in-
flammatory cytokines [TNF-a, IL-1b], anabolic factors [TGFb, TIMP3, bFGF], and
catabolic factors [ADAMTS4, 5, and MMP3, 13].
Results: In vivo study: In Saf-O-staining, the defects in Group A were covered with
hyaline-like cartilage at 3 and 6 weeks. Average modified WAKITANI scores were
significantly better in group A than group B and C at 3 and 6 weeks [3weeks: group
A: 6.2, group B: 7.8, group C: 9.8 (p<0.05); 6weeks: group A: 6.4, group B: 7.6,
group C: 8.6 (p<0.05)]. At 1 and 2 weeks, there was no significant difference in
the average scores in all groups. Low-grade synovitis occurred in both groups at
each week. There were no significant differences in average synovitis scores be-
tween the two groups at each day. In vitro study: Both 1mg/ml and 10mg/ml of
TNC up-regulated the expression of TNFa and IL-1b. 10mg/ml TNC up-regulated
the expression of endogenous TNC, TGFb, TIMP3 and ADAMTS4, MMP3, MMP13,
but 10mg/ml of TNC down-regulated the expression of ADAMTS5.
Conclusion: This study demonstrated that full-thickness osteochondral defects in
mice with 100mg/ml of TNC were successfully repaired with hyaline-like cartilage
without exacerbating synovitis. The in vitro study demonstrated that TNC up-reg-
ulates itself and anabolic factors. TNC up-regulated the expression of ADAMTS4,
but down-regulated the expression of ADAMTS5, which contributed to cartilage
degradation. We consider that TNC could repair the cartilage using these
mechanisms.
http://dx.doi.org/10.1016/j.jot.2016.06.06675
ADVANCED MUSCULOSKELETAL IMAGING SYSTEMS ADOPTED FOR STUDYING A
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DEPLETION-INDUCED OSTEOPOROSIS
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Introduction: Epimedium is a usual herb used in herbal Fufang (formula) in TCM to
strengthen bone and Icaritin is the most potential metabolite of Epimedium. This
study was designed to develop an Icaritin-containing bone targeting delivery sys-
tem for evaluation of its prevention effects on estrogen-depletion induced osteo-
porosis in experimental model.
Subjects and Methods: To evaluate the efficacy of Icaritin with targeting liposome
delivery system on prevention of osteoporosis in vivo by analyzing the bone quality
and microarchitecture by micro-computed tomography (micro-CT) and the organ
distribution of the delivery system by using Xenogen IVIS spectrum system. (DSS6)-
liposome-Icaritin was firstly synthesized by thin film evaporation method with
extruding through polycarbonate filter membranes to obtain unilamellar vesicles.
Then the bone targeting molecules DSS6 were attached to the surface of the
vesicles. Eighty 4-month-old C57/BL6 female mice were divided into 9 groups
(nZ10), including Baseline (BL), Sham surgery (SH), Ovariectomized only (OVX),
Estradiol for oral administration (O-E2), Icaritin for oral administration (O-ICT),
low dose (8 mg/kg, 1/week) targeting liposome delivery system with Icaritin
injected via caudal vein (IV-LIP+ICT+DSS6-L), high dose (8 mg/kg, 2/week) targeting
liposome delivery systemwith Icaritin injected via caudal vein (IV-LIP+ICT+DSS6-H),
liposome delivery systemwith Icaritin injected via caudal vein (IV-LIP+ICT, 8 mg/kg,
2/week). Except in the BL and SH groups, ovariectomy surgery (OVX) was performed
on other mice. Administration of gavage and IV injection were applied respectively
from the day right after the surgery and lasted for 6weeks. All micewere sacrificed 6
weeks after surgery. Lumbar spine and the lower limbswere harvest for bone quality
analysis. Proximal tibia was scanned by micro-CT (Scanco micro-CT 40). Trabecular
bone was identified and the parameters including bone mineral density (BMD),
90 Session: Disease & Treatmenttrabecular bone number (Tb.N), trabecular bone thickness (Tb.Th) and trabecular
bone separation (Tb.Sp) were analyzed for evaluation of bone quality and micro-
architecture. For confirming the specificity of the targeting delivery system, we
usedXenogen IVIS spectrumto semi-qualify the distributionof bone targeting system
signals in vivo by injecting labelled targeting delivery system into four-month-old
C57/BL6 normal female mice.
Results: From the micro-CT results, by comparing to the OVX group, bone quality
in groups with IV injection were enhanced reflected in the increased BMD
(p<0.05), bone volume (p<0.05), trabecular bone number and connectivity den-
sity (p<0.05) and decreased in trabecular bone separation (p<0.05). Also the
efficacy of the targeting Icaritin delivery system tended to be dosage dependent
(BV increased 14.16% in high dose group, Tb.N increased 10.34% and connectivity
density of trabecular bone increased 19.70%). Moreover from the Structure Model
Index (SMI) value, we conclude that the morphology of trabecular bone in Icaritin
injection groups tended more to be plate-like: SMI (OVX) Z 2.190.30, SMI
(IV-AP8+LPS+ICT-1) Z 2.070.36, SMI (IV-AP8+LPS+ICT-H) Z 2.010.23). From
the organ distribution map of Xenogen IVIS spectrum, there were more signals
retain in bone 72 hours after injection by comparing to the delivery system
without bone targeting DSS6.
Discussion and Conclusion: The novel bone-targeting delivery system carrying
osteopromotive phytomolecule Icaritin was confirmed to be capable of preventing
oestrogen depletion-induced osteoporosis in a dose dependent manner.
http://dx.doi.org/10.1016/j.jot.2016.06.06784
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Introduction: Osteoarthritis (OA) is the most common chronic condition of the
joints affecting approximately 27 million adults in the United States alone. The su-
perficial layer of mature articular cartilage is the first line of defence against OA
initiation. It has 2e4 layers of flat cells expressing unique molecules, such as pro-
teoglycan 4 (Prg4, lubricin) and contains a fine network of collagen fibrils that are
oriented horizontally and parallel to the articular surface [1]. Its multifaceted
roles include, but are not limited to, producing lubricant proteins, harbouring
chondroprogenitors, resisting shear stresses, serving as a gliding surface, and
isolating deeper layers from synovial fluid [1]. In OA, degenerative changes initiate
with cellular disorganization, gradual stiffening, and irregular surface of this layer
[2e4]. Despite the critical role of superficial chondrocytes in maintaining articular
cartilage and in preventing OA, its regulation by growth factors and hormones are
still largely unknown.
Objective: To investigate the function of epidermal growth factor receptor (EGFR)
in articular cartilage development and osteoarthritis (OA) progression in geneti-
cally modified and surgical mouse models.
Methods: Animals and surgery- Cartilage-specific Egfr CKO (Col2-Cre EgfrWa5/f)
mice and their Wa5 (EgfrWa5/f) and wild-type (WT, Col2-Cre Egfrf/+ and Egfrf/
+) siblings were generated by breeding Col2a1-Cre, EgfrWa5/+, and Egfrf/f
mice. EgfrWa5 codes for a kinase-dead, dominant negative receptor. To induce
OA, male mice at three months of age were subjected to destabilization of the
medial meniscus (DMM) surgery at the right knees and sham surgery at the left
knees. Their knee joints were examined by histology, immunohistochemistry,
nano-indentation, and microCT with or without destabilization of the medial
meniscus (DMM) surgery. Primary chondrocytes were used to study the direct ef-
fects of activating EGFR on chondrocytes. Finite element models were built to
calculate the mechanical loading on cartilage and subchondral bone plate (SBP) af-
ter DMM.Results: EGFR activity is more dominant in the superficial layer. Compared to con-
trols, adult CKO mice had fewer superficial chondrocytes (11.3% of WT), lower
cartilage surface stiffness (28.7% of WT), and less boundary lubricant secretion
and developed early OA symptoms (Mankin: WTZ1.20.3; Wa5Z1.60.4
CKOZ6.80.5). In culture, activating EGFR is critical for maintaining chondrocyte
numbers, preventing hypertrophy, and promoting Prg4 expression in an EGFR-
dependent manner. After DMM, CKO mice quickly developed the most severe OA
phenotype including a complete loss of cartilage at the medial side (Mankin:
WTZ60.5; Wa5Z11.50.5 CKOZ14.00.0) and an increase in joint pain (Paw
Withdrawal Threshold: CKOZ29.7% of WT). They also developed subchondral
bone sclerosis precisely under the cartilage damage area (4.5 folds of WT), owing
to elevated mechanical stress (12.6 folds of WT) and a reduction of sclerostin in
the subchondral bone plate.
Conclusions: Our work establishes EGFR signalling as a novel and important regu-
lator of articular cartilage that prevents osteoarthritis initiation and elucidates the
mechanism of subchondral bone symptoms associated with late osteoarthritis.
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SDF-1a, A PROGNOSTIC PROTEIN MARKER IN SYNOVIAL FLUIDS FOR PTOA IN
ACL DEFICIENT KNEES?
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Introduction: Knees with history of tears in the anterior cruciate ligament (ACL)
are more prone to develop post-traumatic osteoarthritis (PTOA) [1]. However,
there are no preventive treatments available for this disease, since factors that
can be used to predict and monitor the degeneration in ACL deficient knees are
still under investigation. Recent studies indicated that SDF-1 levels in synovial
fluids (SF) are elevated in OA joints and are positively correlated with radiographic
severity of knee OA [2]. Based on this finding, we hypothesised that levels of SDF-
1a in SF from patients with more severe ACL injuries may be higher than those from
patients with less severe injuries.
Subjects & Methods: SF samples (N Z 96) were collected from patients (35 fe-
males, 61 males, age ranging from 14 to 55 years old) with ACL ruptures immedi-
ately prior to the revision surgery. Based on the injury duration (ID) (the length of
time between injury and surgery), those samples were categorised into 3 groups:
acute (ID  1.0 months), sub-acute (1.0 months < ID  3.0 months), and chronic
(ID > 3.0 months). The level of total proteins in supernatants was measured
with a bicinchoninic acid assay. The content of SDF-1a was quantitated with a hu-
man specific solid phase sandwich enzyme-linked immunosorbent assay. The dif-
ference between groups was compared with an unpaired Student t-test.
Results: The acute group showed the highest total protein level in SF (mean 
S.D.: 32.8  7.4 mg/mL; median: 33.6 mg/mL; N Z 47), which was followed by
the sub-acute group (30.3  13.9 mg/mL; 26.4 mg/mL; 31) and then by the chronic
group (23.3  10.9 mg/mL; 21.9 mg/mL; 18). The difference in the level of total
proteins between the acute group and the chronic group was extremely statisti-
cally significant (P Z 0.0001). The same pattern was observed in SDF-1a content
analysis: 3,240.4  1,339.4 pg/mL (median: 3,158.8 pg/mL) in the acute group,
2,976.9  889.2 pg/mL (median: 3,024.5 pg/mL) in the sub-acute group, and
2,392.6  1,241.7 pg/mL (median: 2,084.0 pg/mL) in the chronic group. The
average level of SDF-1a in the acute group was also significantly higher than
that in the chronic group (P Z 0.023).
Discussion & Conclusion: Our results from analysing SF samples from patients
with ACL injuries indicated that the levels of total proteins and SDF-1a in the
acute group were markedly higher than those in the chronic group, which sup-
ports our hypothesis. Presumably, patients in the acute group with a shorter
ID may sustain more severe ACL injuries than the ones in the chronic group
with a longer ID. The injury severity may positively correlate with the possibility
of PTOA onset in the injured knees [3]. Based on this theory, therapies targeting
SDF-1a might be effective in preventing the development of PTOA in ACL defi-
cient knees.
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